 ADENOCARCINOMA OF LUNG, RESPONSE TO TYROS
|
ADENOCARCINOMA OF LUNG, SOMATIC
|
AORTIC ANEURYSM, FAMILIAL THORACIC 7
|
BREAST CANCER, SUSCEPTIBILITY TO
|
CARDIOFACIOCUTANEOUS SYNDROME 1
|
CARDIOFACIOCUTANEOUS SYNDROME 3
|
CARDIOFACIOCUTANEOUS SYNDROME 4
|
CATARACT 6, AGE-RELATED CORTICAL
|
CHRONIC MYELOID LEUKEMIA, RESISTANT TO IMATINIB
|
COFFIN-LOWRY SYNDROME
|
COFFIN-LOWRY SYNDROME, MILD
|
COLON CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC, INCLUDED;;
|
DEFICIENCY
|
DIABETES MELLITUS, TYPE II
|
ENDOCRINE-CEREBROOSTEODYSPLASIA
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
FG SYNDROME 4
|
GLYCOGEN STORAGE DISEASE IXC
|
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1
|
IN
|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
LYMPHOMA, NON-HODGKIN, SOMATIC
|
LYMPHOPROLIFERATIVE SYNDROME 1
|
MALFORMATIONS
|
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME
|
MELANOMA, MALIGNANT, SOMATIC
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA
|
MENTAL RETARDATION, X-LINKED 19
|
MENTAL RETARDATION, X-LINKED 30
|
MENTAL RETARDATION, X-LINKED, WITH NYSTAGMUS
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB
|
MYASTHENIC SYNDROME, CONGENITAL, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR
|
NEPHRONOPHTHISIS 9 (NPHP9)
|
NEUROPATHY, HEREDITARY SENSORY, TYPE II
|
NONSMALL CELL LUNG CANCER, RESISTANCE TO TYROSINE KINASE INHIBITOR
|
NONSMALL CELL LUNG CANCER, RESPONSE TO TYROSINE KINASE INHIBITOR IN,
|
NOONAN SYNDROME 7
|
OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY
|
OGUCHI DISEASE 2
|
PARKINSON DISEASE 8, AUTOSOMAL DOMINANT
|
PEUTZ-JEGHERS SYNDROME
|
PHEOCHROMOCYTOMA, INCLUDED
|
PHEOCHROMOCYTOMA, SOMATIC, IN
|
PROSTATE CANCER, PROGRESSION AND METASTASIS OF
|
PULMONARY HYPERTENSION, PRIMARY, 1
|
PULMONARY HYPERTENSION, PRIMARY, 1, WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA
|
PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED, INCLUDED
|
PULMONARY VENOOCCLUSIVE DISEASE
|
RENAL AGENESIS
|
RETINITIS PIGMENTOSA 38
|
RETINITIS PIGMENTOSA 62
|
RETINITIS PIGMENTOSA 62 (RP62)
|
SELECTIVE T-CELL DEFECT
|
SHORT RIB-POLYDACTYLY SYNDROME 2A (SRPS2A)
|
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA
|
SOMATIC
|
SPERMATOGENIC FAILURE 5
|
SPINOCEREBELLAR ATAXIA 14
|
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE
|
T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC
|
TESTICULAR TUMOR, SOMATIC
|
THROMBOCYTOPENIA 2
|
THYROID CARCINOMA, FAMILIAL MEDULLARY
|
THYROID CARCINOMA, FAMILIAL MEDULLARY, INCLUDED
|
THYROID CARCINOMA, FOLLICULAR, SOMATIC, INCLUDED
|
THYROID CARCINOMA, PAPILLARY, SOMATIC, INCLUDED;;|
|
THYROID CARCINOMA, SPORADIC MEDULLARY, INCLUDED;;
|
VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL
|
Catalytic domain of Phototropin-like Protein Serine/Threonine Kinases. Serine/Threonine Kinases (STKs), Phototropin-like subfamily, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The phototropin-like subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. Included in this subfamily are plant phototropins and predominantly uncharacterized fungal STKs whose catalytic domains resemble the phototropin kinase domain. One protein from Neurospora crassa is called nrc-2. Phototropins are blue-light receptors that control responses such as phototropism, stromatal opening, and chloroplast movement in order to optimize the photosynthetic efficiency of plants. They are light-activated STKs that contain an N-terminal photosensory domain and a C-terminal catalytic domain. The N-terminal domain contains two LOV (Light, Oxygen or Voltage) domains that binds FMN. Photoexcitation of the LOV domains results in autophosphorylation at multiple sites and activation of the catalytic domain. Neurospora crassa nrc-2 plays a role in growth and development by controlling entry into the conidiation program.
No pairwise interactions are available for this conserved domain.
